Metabolites and metabolic pathways associated with glucocorticoid resistance in pregnant African-American women

Elizabeth Corwin a,*, Anne L. Dunlop b, Jolyn Fernandes c, Shuzhao Li c, Bradley Pearce d, Dean P. Jones c

a Columbia University, United States
b Emory University School of Medicine and School of Nursing, Emory University, United States
c School of Medicine, Emory University, United States
d Rollins School of Public Health, Emory University, United States

ARTICLE INFO

Keywords:
Metabolomics
Glucocorticoid resistance
Health disparity
Pregnancy
Stress
Metabolites
Inflammation

ABSTRACT

Glucocorticoid resistance (GR) is associated with exposure to chronic stress and an increased risk of metabolic and inflammatory disorders in both animal and human populations. Studies on ethnic disparities highlight the African-American (AA) population as having a high propensity to both GR and chronic stress exposure. Glucocorticoids and inflammation play a very important role in pregnancy outcome and fetal development. To date, however, the metabolites and metabolic pathways associated with GR during pregnancy have not been identified, obscuring the mechanisms by which adverse health consequences arise, and thus impeding targeted therapeutic intervention. The objective of this study was to perform untargeted high-resolution metabolomics (HRM) profiling on 273 pregnant AA women, to identify metabolites and metabolic pathways associated with GR during the first trimester of pregnancy and to evaluate their cross-sectional association with birth outcomes and psychosocial variables related to chronic stress exposure. For this study, GR was determined by the concentration of dexamethasone required for 50% inhibition (Dex IC50) of the cytokine tumor-necrosis factor alpha (TNF-α) release in vitro in response to a standard dose of lipopolysaccharide. The results for Metabolome-Wide Association Studies (MWAS) and pathway enrichment analysis for serum metabolic associations with Dex IC50, showed energy (nicotinamide and TCA cycle), amino acid, and glycosphingolipid metabolism as top altered pathways. Bioinformatic analysis showed that GR, as indicated by elevated Dex IC50 in the pregnant women, was associated with increased inflammatory metabolites, oxidative stress related metabolites, increased demand for functional amino acids to support growth and development, and disruption in energy-related metabolites. If confirmed in future studies, targeting these physiologically significant metabolites and metabolic pathways may lead to future assessment and intervention strategies to prevent inflammatory and metabolic complications observed in pregnant populations.

1. Introduction

Glucocorticoids (GC) are steroid hormones under the influence of the hypothalamic-pituitary-adrenal (HPA) axis. GC mediate their actions by binding to glucocorticoid receptors, becoming a ligand dependent transcription factor that regulates key physiological events through target gene modulation in inflammation, glucose and fat metabolism, and cellular differentiation [1]. An important clinical pathological outcome observed is glucocorticoid resistance (GR). GR is identified in vitro by an increase in the dose of dexamethasone required to inhibit 50% (i.e., the IC50) of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in the presence of the inflammatory agent bacterial lipopolysaccharide (LPS) [2–4]. Mechanisms for the manifestation of GR are still under investigation, however physiological stimuli such as chronic stress can activate the HPA axis thereby regulating plasma GC levels and GC action [5,6]. Genetic and epigenetic studies have shown that early exposure to altered glucocorticoid response (as early as beginning in utero) programs changes in neuroendocrine and immune mechanisms [7, 8]. These altered glucocorticoid responses may further lead to increased vulnerability to adverse health outcomes later in life such as asthma [7];
insulin resistance [9]; inflammatory disease [10], metabolic syndrome [11], and potentially, adverse pregnancy outcomes [12,13]. Hence understanding what metabolites and metabolic pathways are associated with GR becomes necessary, in order ultimately to delineate mechanisms that lead to GR and identify therapeutic targets to prevent GR and its consequences.

Recent advances in metabolomics offer an opportunity to take this next step. Metabolomics includes multiple technologies that allow the identification of specific metabolites and complex metabolic pathways associated with health outcomes of interest [14,15]. A recent state-of-the-science White Paper, emphasizes that an individual’s metabolic state, that is, the metabolites and metabolic pathways present, reflects the existing complex interactions between genome, proteome, diet, environmental exposures, and the gut microbiome [16]. These metabolites and pathways provide a real-time phenotype that can be screened to identify metabolic trends associated with adverse outcomes, potentially leading to early and targeted assessment and intervention strategies that influence those metabolites and pathways [15]. Metabolomics has been applied previously to identify biomarkers that associate with adverse pregnancy outcomes, including preterm birth, gestational diabetes mellitus, preeclampsia and small for gestational age (SGA) [17–20], but has not been utilized to identify pathways related to GR or other measures of chronic stress exposure in pregnant women.

Importantly, ethnic disparities have been observed in glucocorticoid induced insulin resistance, wherein African Americans were more insulin resistant than Caucasian Americans under both placebo and dexamethasone treatments [9]. Compared to Caucasians, the National Academy of Medicine [21] and others (Kramer et al., 2011a; Mutambudzi et al., 2017; Parker and Douglas, 2010), have also identified stress as a key contributor to the health disparity in pregnancy outcomes experienced by AA women. Based on these ethnic disparities, and the future risk for GR-induced symptoms of metabolic syndrome in AA women, the present study was focused on utilizing metabolomics to identify metabolites and metabolic pathways associated with graded Dex IC50 response within the first trimester in AA women and to evaluate cross-sectional associations in light of personal factors such as age, body mass index (BMI), parity, and insurance status, and psychosocial measures of stress including adverse childhood experiences and exposure to discrimination. The potential to expose metabolites and metabolic pathways associated with GR and other measures of stress exposure during the first trimester of pregnancy, and to investigate their associations with pregnancy outcomes, will ultimately increase our ability to develop, deliver, and evaluate targeted clinical interventions that will improve maternal and fetal/infant health outcomes.

2. Materials and methods

Study population. Participants were drawn from women enrolled in the Emory University African American Vaginal, Oral, and Gut Microbiome in Pregnancy Cohort [22], for which pregnant US-born women who self-identify as African American (AA) are recruited from two hospitals in Atlanta, GA: a private hospital affiliated with Emory University that provides services for a socioeconomically and educationally diverse population and a county-supported hospital that provides services to the low-income and underserved. Both are staffed by Emory Obstetrics and Gynecology faculty. AA women presenting to the hospital-affiliated clinics for prenatal care between 8-14 weeks gestation, as determined by standard criteria based upon last menstrual period and/or first trimester ultrasound, were offered enrollment if they met the following inclusion criteria: 1) US-born black by self-report; 2) between 8-14 weeks gestation with a singleton pregnancy (verified by clinical record); 3) able to comprehend written and spoken English; 4) between 18-40 years of age; and 5) experiencing no chronic medical condition or taking prescribed chronic medications aside from prenatal vitamins (verified by clinical record). Women selected for inclusion in this study (N = 273) are a subsample of those enrolled into the Emory University African American Vaginal, Oral, and Gut Microbiome in Pregnancy Cohort between June, 2014, and January, 2017, for whom sufficient venous blood sample was available for determination of GR and metabolomics assays. The present study was approved by the Emory University Institutional Review Board; all participants provided written informed consent prior to enrollment and participation.

Sample collection and clinical data. At the 8-14 week enrollment encounter, participants completed questionnaires and provided biological samples as described in detail previously [22]. Briefly, women were informed of the study during their first prenatal visit by the prenatal clinic receptionist and those interested in learning more, then met with the study coordinator. After hearing details of the study and initial inclusion criteria, women who continued to express interest in participating provided informed consent after which they were accompanied to the clinical laboratory where a venous blood sample, in addition to that required for their initial prenatal visit, was collected for later analysis of in vitro WBC Dex IC50, an indicator of GR [3,23,24] and (5) high-resolution serum metabolomics. After completing all biological sample collections, women returned to the waiting room where they next completed demographic and health questionnaires providing information on: (1) Maternal race, based on self-report; (2) Maternal age, parity, prenatal health insurance status (Medicaid, private) at the time of enrollment; (3) Psychosocial measures relevant to the analyses of this study including participants’ exposure to chronic stress and racial discrimination; (4) Fetal age at the time of the 1st trimester prenatal exam as determined by fetal ultrasound and/or last menstrual period; (5) Infant gestational age at delivery or the occurrence of a spontaneous abortion (e.g., miscarriage), defined as the loss of a fetus before the 20th week of pregnancy, and ascertained after delivery from the prenatal record by medical chart abstraction using a standardized chart abstraction tool; and (6) Body Mass Index (BMI) calculated from patients’ measured height at the first prenatal visit and patient-report of pre-pregnancy weight at the first visit.

In Vitro Dexamethasone Resistance Assay. Blood collected at the first prenatal visit (weeks 8–14 of gestation) was processed and analyzed to evaluate GR as described previously [25]. Briefly, whole blood was diluted 10:1 with sterile phosphate buffered saline, and 450 μL of this mixture was incubated in duplicate with LPS (from Escherichia Coli Serotype 055:B5, Millipore-Sigma; final concentration 30 ng/mL) for 24 h in the absence or presence of serial dilutions of dexamethasone (Millipore-Sigma, 10−9 to 10−5 M) in 24-well cell culture plates at 37 °C in 5% CO2. Culture well contents were centrifuged at 1000 X g for 10 min, and supernatants aliquoted and stored at −80 °C until assayed by ELISA (BD Biosciences) for TNF-α, a frequently used indicator cytokine, including in 50% of the GR-related studies identified in a recent meta-analysis [4]. The DEX concentration required to suppress 50% of the LPS-induced cytokine response was determined from supernatant concentrations of TNF-α using dose-response curves fitted by Prism (GraphPad Software, La Jolla, CA).

High-Resolution Metabolomics. High-resolution metabolomics (HRM) was completed using established methods [26,27]. A total of 50 μL of serum sample was treated with 100 μL of ice-cold LC-MS grade acetonitrile (Sigma Aldrich) containing 2.5 μL of internal standard solution with eight stable isotopic chemicals selected to cover a range of chemical properties. Following addition of acetonitrile, serum was equilibrated for 30 min on ice, and the precipitated proteins were removed by centrifugation (16.1 × g at 4 °C for 10 min). Resulting supernatants were maintained at −4 °C until analysis. Serum samples were analyzed in batches of 20; each batch included duplicate analysis of pooled human plasma (QStd) for quality control purposes.

Samples were analyzed in triplicate with 10 μL injections using hydrophilic interaction liquid chromatography (HILIC) column in positive electrospray ionization (ESI) mode (Thermo Scientific Dionex Ultimate 3000RSLCnano, Thermo Scientific Orbitrap Fusion Tribrid Mass Spectrometer). The high-resolution mass spectrometer was operated in full scan mode at 120,000 resolution and mass-to-charge ratio (m/z) range.
85–1275. Raw data files were extracted and aligned using apLCMS [28] with modifications by xMSanalyzer [29]. Uniquely detected ions consisted of accurate mass m/z, retention time and ion abundance, referred to as m/z features. Prior to data analysis, m/z features were batch corrected using ComBat [30].

**Metabolite Annotation.** Metabolite features were annotated using xMSannotator using HMDB database, wherein the confidence scores for annotation are derived from a multistage clustering algorithm [31]. Further identification of the selected metabolites by criteria of Schymanski [32] in combination with xMSannotator [31], included metabolite identification through matching to both m/z and retention time of a previously characterized authenticated chemical standard (level 1); annotated compounds matching m/z from databases wherein M+H is present and isopes co-elute (level 2); annotated compounds matching m/z from databases wherein M+H is present and pathway metabolites present (level 3); m/z match from database within 5ppm tolerance with unique identifier (level 4). Database used for annotation include HMDB (Human Metabolome Database, http://www.hmdb.ca/) [33] and KEGG (Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/) [34]. Additional manual search was done using METLIN (http://metlin.scripps.edu/index.php) at 5 ppm tolerance [35].

**Bioinformatics analysis.** A total of 16,481 m/z features were detected, which were further filtered to retain only features with non-zero values in >80% in all individuals and >50% in all technical replicates. The remaining 8830 m/z features were log2 transformed, quantile normalized and used for further regression based statistical analysis. A linear regression model adjusted for demographic covariates such as age, BMI and parity, was used to select metabolic features associated with increasing GR (Dex IC50) in a metabolome-wide-association study (MWAS). Threshold at P < 0.05 without adjustment for multiple comparisons and for q < 0.05 after correction for false discovery rate (FDR) was applied. FDR correction protects against type 1 error but not type 2 statistical error. Significant features (raw P < 0.05) were further studied by pathway enrichment analyses using mumichog 1.0.9 [36]. This approach protects against type 2 statistical error and protects against type 1 statistical error by permutation testing in pathway enrichment analysis by including all features at P < 0.05 [37]. Hierarchical cluster analysis (HCA) and partial least square discriminant analysis (PLS-DA) were used for comparison of the 1094 significant features obtained from lmreg model and plotted for quintile 1 (n = 55, Dex IC50 < 5348 pM) and quintile 5 (n = 55, Dex IC50 > 12898 pM) (raw P < 0.05) using Metaanobanalyst [38]. Boxplots were plotted in R v.3.2.3.

**Statistical Analyses.** Descriptive analyses were conducted for the study population with median (range) and percentages (n) computed for demographic variables including age, BMI, parity and insurance status, each previously shown to impact pregnancy outcomes [39–43]. Spearman correlation was used to test for associations between Dex IC50 and demographic data, while crude odds ratio (OR) and adjusted OR were calculated using logistic regression modeling for pregnancy outcomes and psychosocial variables. Dex IC50 was used as a continuous variable in the linear regression analyses.

### 3. Results

#### 3.1. Demographics and clinical parameters

A total of 273 AA women at 8-14 weeks of gestation met criteria for inclusion in this study. Demographic and clinical characteristics for all 273 AA pregnant women, including serum Dex IC50 levels, maternal age in the first trimester, body mass index, parity, insurance status and education are summarized in Table 1. The concentration of dexamethasone required to suppress 50% of the LPS-induced TNF-α response (Dex IC50), a measure for GR, is depicted as a bar plot for each of the participating subjects (Fig. 1) and the range of values are presented as quintiles in Table 1. The range of Dex IC50 values for the study population was 125-fold and the median (range) was 9524 pM (246 - 30,888 pM). The median Dex IC50 for Quintile Q1, was 3593 pM and highest quintile, Q5 was 16,504 pM. Demographic survey results show that the median age for the study sample was 24 years; 17.9% of the subjects were greater than 30 years of age, and the majority were in the age range of 20–29 years (69.6%). The median BMI was 26.1 kg/m² and ranged from 16.5 to 56.5 kg/m²; with 54.6% of the study population overweight. The study sample comprised of 48.7% subjects without previous birth history. A total of 77.3% of the study population had medical insurance from the government and 22.7% had private medical insurance. The majority of subjects either graduated high school (35.9%) or attended some college/technical school (86%). None of the demographic variables reported were correlated with serum Dex IC50 values.

### Table 1 Demographic and clinical characteristics of the study population. (Pregnant AA women, n = 273, *P < 0.05).

| Characteristics                          | Results | Quintile 1 | Quintile 5 |
|------------------------------------------|---------|------------|------------|
| Number of subjects                       | 273     | 55         | 55         |
| DexIC50 (pM)                             | 9524    | 3593       | 16504 *    |
|                                            | (246–30,888) | (246–5348) | (12898–30888) |
| Age, y                                   | 24 (18–35) | 24 (19–35) | 23 (18–35) |
| <20 y                                    | 54 (12.5%) | 5          | 8          |
| 20–29 y                                  | 190 (69.6%) | 31         | 37         |
| ≥30 y                                    | 49 (17.9%)  | 14         | 8          |
| BMI (kg/m²)                              | 26.1    | 26.6       | 24.6       |
|                                          | (16.5–56.5) | (18.4–56.5) |          |
| Parity *                                 | 0       | 133 (48.7%)| 22         | 28         |
| 1                                        | 79 (28.9%) | 20        | 14         |
| 2                                        | 39 (14.3%) | 9        | 6          |
| 3                                        | 18 (6.6%)  | 3        | 6          |
| 4                                        | 4 (1.5%)   | 1        | 1          |
| Insurance Status                         |         |           |            |
| Government                               | 211 (77.3%) | 44       | 42         |
| Insurance                                | 62 (22.7%)  | 11       | 13         |
| Private Insurance                        |         |           |            |

* median (range).  
b n (%).
3.2. Metabolome wide association study of glucocorticoid resistance

In order to investigate the global serum metabolic alterations associated with GR, we performed a metabolome wide association study of untargeted serum metabolic features identified by HRM. Using a linear regression model with Dex IC50 values as a continuous variable, a total of 75 out of 8830 were found as discriminatory features at a false discovery rate (FDR) of 0.25 and 1092 m/z features at a raw P value < 0.05. This selection was adjusted for demographic covariates such as age, BMI and parity. The Dex IC50 values, age, BMI and parity for each individual subject is provided in Supplemental Table 1. The type 1 Manhattan plot (-log10(P) versus m/z) shows that these discriminatory features comprise a broad range of m/z (Fig. 2A), wherein red represents features that are positively and blue represents features negatively associated with Dex IC50. The top dotted horizontal line marks FDR 0.25 threshold and the bottom dotted line represents raw P value < 0.05 threshold (Fig. 2). Two thirds of all the 1092 discriminatory features were negatively associated with Dex IC50. Also 73% of features with an m/z less than 400 were positively associated with Dex IC50, while 84% of features greater than m/z 400 were negatively associated. The type 2 Manhattan plot (-log10(P) versus chromatographic retention time) showed that 62% of the discriminatory features elute within 60 s (Fig. 2B). 78% of these early eluting features were negatively associated with Dex IC50, while the later eluting features comprised mostly of positively associated metabolic features, consistent with an amino acid elution pattern. The mass to charge, retention time and P-value for the 1092 discriminatory metabolites is provided in Supplemental Table 2.

Hierarchical cluster analysis plot (HCA) of the 1092 features showed that a total of 392 m/z features increased while 700 m/z features decreased with an increase in Dex IC50 value as graphically represented by the highest Dex IC50 quintile (Q5, Dex IC50 mean ± SEM; 17,685 ± 590.1, n = 55) versus the lowest quintile (Q1, Dex IC50 mean ± SEM; 3552 ± 169.5, n = 55) (Fig. 3A). These 1092 discriminatory metabolites selected by linear regression for all 273 AA women were further assessed by PLS-DA to identify the top discriminatory features that separated individuals in the highest Dex IC50 quintile, Q5, from the lowest quintile, Q1. In the 3-dimensional PCA score plot (Fig. 3B), principal component 1 accounted for 19.2% of the variance and principal component 2 accounted for 11.2%. The top 50 metabolites (VIP > 1.5) responsible for the separation of Q1 and Q5 along principal component 1 are presented in Fig. 3C. These metabolites were annotated using xMSannotator with KEGG, Metlin and HMDB databases. These metabolites were comprised of increases in inflammatory markers such as glycosphingolipids – sphingomyelin, ceramides, ganglioside; and glycerophospholipids - PE (phosphatidylethanolamine), PG (phosphatidylglycerol), glycerophosphocholine and diglycerides (DG). The list also extended to other inflammatory markers such as oxidized LTA4 imidazole acetol phosphate and cholesterol ester (CE); oxidative stress related metabolite hypoxanthine and pentose phosphate pathway metabolite ribose phosphate, all of which increased with increases in Dex IC50 value.

3.3. Metabolic pathways and key metabolites associated with glucocorticoid resistance

To investigate how these 1092 discriminatory m/z features obtained by the linear regression model were enriched in metabolic pathways, pathway enrichment analysis was performed using Mummichog [36]. Results showed the top 4 discriminatory pathways that were significantly altered by glucocorticoid resistance (P < 0.05). These included nicotinamide metabolism (P = 0.004); amino acid metabolism (P = 0.005); TCA cycle (P = 0.01) and glycosphingolipid metabolism (P = 0.04) (Fig. 4). The median and mean were represented as a solid line and short horizontal line respectively within each box. A number of key amino acids included in nicotinamide and amino acid metabolism increased with increase in Dex IC50 and comprised of metabolites such as glutamine (P = 0.0295), aspartate (P = 0.0385) and arginine (P = 0.0335) (Fig. 5A-C). Glycosphingolipids are an integral part of the cell membrane and play an important role in cell adhesion and as signaling molecules. In the glycosphingolipid metabolism, sphingomyelin hydrolysis is a major pathway for stress-induced ceramide generation [44]. Our results show that sphingomyelin (P = 0.0109) and multiple ceramide species including lactosylceramide (P = 0.0023) increased with increase in Dex IC50 values in the cohort, supporting the evidence for increased inflammation with increased Dex IC50 (Fig. 5D–E). Leukotrienes are eicosanoid lipid mediators of inflammation and the results show that leukotriene (P = 0.0090) also increased with increasing Dex IC50 (Fig. 5F). Energy metabolites such as oxaloacetate (P = 0.0391) and phosphoenolpyruvate (P = 0.0475) also increased with increased Dex IC50, suggesting disruption in energy metabolism (Fig. 5G–H). Details on the identification of metabolites significantly associated with glucocorticoid resistance in the 273 pregnant AA women are provided in Supplemental Table 3.
3.4. Evaluation of pregnancy outcomes associated with glucocorticoid resistance

In order to determine the association of increased GR with adverse pregnancy outcomes including preterm birth and spontaneous abortion, odds ratio with and without adjustment for confounding factors was calculated (Supplemental Fig. 1). Results for adverse pregnancy outcomes showed that women with increased concentrations of Dex IC50 did not have increased odds of gestational age for birth <37 wk (OR = 1.88, 5%CI: 0.74, 95%CI: 4.78; P = 0.18), early term spontaneous birth (OR = 1.13, 5%CI: 0.45, 95%CI: 2.86; P = 0.80), preterm spontaneous birth (OR = 2.03, 5%CI: 0.6, 95%CI: 6.95; P = 0.26) or spontaneous abortion (OR = 2.26, 5%CI: 0.38, 95% CI: 13.51; P = 0.37). The results did not reach statistical significance even after adjustment for age, BMI and parity.

3.5. Evaluation of psychosocial variables with glucocorticoid resistance

Glucocorticoid resistance has been reported in populations exposed to chronic stress including, among others, women suffering from post-traumatic stress syndrome [45]. African American women in particular are more often exposed to chronic stress including perceived racism [46], neighborhood violence [47,48], and poverty [49] compared to Caucasian women and are also at a notably higher risk for nearly all types of adverse maternal, fetal, and infant outcomes [21,50,51]. In order to evaluate the strength of the association between GR and psychosocial factors in the current study population, odds ratio with and without adjustment for confounding factors was calculated (Supplemental Fig. 2). Results showed that there was no association between increased concentrations of Dex IC50 and psychosocial events such as adverse childhood experiences (ACE; OR = 0.73, 5%CI: 0.16, 95%CI: 3.46; P = 0.70), sexual life experience inventory (SLEI; OR = 1.05, 5% CI: 0.36, 95%CI: 3.06; P = 0.93), Krieger experiences of discrimination (KED; OR = 2.03, 5%CI: 0.6, 95%CI: 6.95; P = 0.26) or spontaneous abortion (OR = 2.26, 5%CI: 0.38, 95% CI: 13.51; P = 0.37). The results did not reach statistical significance even after adjustment for age, BMI and parity. The results indicate that GR is not associated with psychosocial stress factors in this study cohort. The data thus suggest that GR could be attributed to a number of factors that may contribute to glucocorticoid resistance.
not be limited to standard chronic stress measures observed in ethnic communities, but could be an outcome of stressors such as environmental exposures [52], lifestyle choices [53] or genetic polymorphisms in glucocorticoid receptors [54].

4. Discussion

In this report, we describe the association between GR as reflected by increasing Dex IC50 during early pregnancy, and altered metabolic pathways in AA women, through serum metabolic phenotyping with high-resolution metabolomics. Glucocorticoids activate multiple biochemical processes that not only alter cell physiology at a systemic level for the mother and the fetus, but also facilitate long term adaption to post-uterine life [55]. Our findings, that GR in pregnant AA women, was associated with inflammatory metabolites, oxidative stress, disruption in energy metabolism and increased demand for functional amino acids essential for growth and development but not with preterm birth or other birth outcomes, may indicate that exposure to chronic stress has implications for fetal and child development rather than birth outcomes. Future study is essential.

Glutamine, aspartate and arginine are considered functional amino acids that alter metabolic processes that improve growth and development [56]. Previous amino acid profiling studies in pregnant women (>25 weeks gestational age) have shown that glutamine, aspartate and arginine are increased in plasma of women with gestational diabetes after adjusting for covariates such as gestational age and BMI [57]. Our results showed increases in these same three functional amino acids in association with increased Dex IC50. While indicating a relationship, given the cross-sectional nature of the study, directional effects of these associations cannot be determined. Moreover, although future studies to determine whether an increase in these amino acids is associated with disorders such as the development of gestational diabetes in subjects with GR are required, serum quantitation of amino acids along with routine laboratory tests, may someday play a role in pregnancy health monitoring to prevent future adverse metabolic outcomes in mother and the fetus.

Normally, circulating cortisol binds to glucocorticoid receptors in the WBC cytoplasm; once bound, the hormone-receptor complex translocates to the nucleus and inhibits further production of NF-kB and other transcription factors that regulate pro-inflammatory cytokine gene expression, limiting further production of pro-inflammatory cytokines [58]. In response to chronic stress, however, GR may develop, suppressing this feedback loop [12,45,59] and establishing a chronic inflammatory milieu. In both animal [60] and human [61,62] studies, biomarkers associated with oxidative stress and inflammation have been linked to adverse birth outcomes and inadequate energy availability early in pregnancy, disrupting fertility and fetal development [63,64]. Chronic inflammation is also associated with adverse health outcomes across the lifespan in non-pregnant populations [65–67], when present during pregnancy, it increases the risk of gestational diabetes and hypertension [68–70], and under some circumstance, maternal depressive symptoms [71] and autism spectrum disorder [72]. Sphingolipids have been implicated as mediators of cell-stress responses as they play an important role in intracellular signal transduction. Sphingomyelins and ceramides are mainly associated with low-density lipoproteins (LDL), thus alluding to their potential atherogenic properties [73]. Increased sphingomyelins and ceramides are associated with cardiovascular diseases [74], insulin resistance [75], type 2 diabetes and obesity [75]. They are also potent activators of the inflammatory cascade [76]. Our results showed that increased Dex IC50 was associated with increased serum sphingomyelin, leukotriene and multiple ceramide species, which indicate that GR within the first trimester is linked to increased inflammation in AA women. These findings may predispose the mother and/or the fetus to adverse outcomes, including maternal metabolic syndrome and insulin resistance, as well as altered fetal development and/or future health risks for offspring [77,78]. Future studies that include assessment of offspring health outcomes are required to better understand the role of GR and early inflammatory metabolic alteration on long term offspring health and development.

Although mechanisms by which systemic and local inflammation associate with adverse health outcomes remain under investigation, inflammation increases oxidative stress [79,80], which could alter energy production and mitochondrial function [81]. Further evidence supports that glucocorticoid receptors (GRs) translocate into mitochondria and modulate mitochondrial gene expression, thereby altering mitochondrial function and impacting energy production [82].
current study does indeed demonstrate that GR observed in pregnant AA women impacts the TCA cycle and suggests energy availability may be compromised with disruption in energy related precursor accumulation.

This study identified a wide range of Dex IC50 concentrations across the AA cohort. The level of Dex IC50 in this population was not associated with age, BMI, parity, pregnancy outcomes, psychosocial factors or standard indicators of SES variables including education or insurance (See Table 1, Supplementary Figs. S1 and S2, and Fig. 6). While GR has been associated with chronic stress measures in other populations [3,23,59,83], inter-comparison within the AA population indicates an association of GR as a function of Dex IC50, with chronic stress related perhaps to a milieu of environmental exposures, lifestyle choices, genetic polymorphisms and psychosocial variables, rather than a single factor. These findings also support the need for future studies to evaluate the contribution of these experiences to adverse birth outcomes comparing AA women to other ethnicities (Fig. 6).

As with most studies, this investigation has limitations. Although results suggest that GR is not associated with adverse birth outcomes in our study cohort, this may be related to small sample size in each group and requires further experimental validation with a larger cohort. With 273 AA women, and although the data show strong correlation of GR with inflammation, energy deficit and amino acid dysregulation, a larger sample size is essential to determine if lack of association between GR and standard chronic stress measures such as SES variables and psychosocial parameters still holds true. The study is also limited by its cross-sectional nature, which makes it impossible to know if the changes in metabolites are a consequence or a cause of GR. Additional information on GR changes across pregnancy and developmental parameters of the child at birth are likewise essential. Another potential limitation is the lack of a non-AA comparison group, which would further strengthen the underpinnings of health disparity, one must take this first look within the disparity group for group-defined risk and protective factors [87,88]. Our study also lacks the measure of serum cortisol within the group, which could further serve as a surrogate for in vitro Dex IC50 measures. However,
based on metabolomics analysis, 18-hydroxycortisol and aldosterone sulfate, both downstream metabolites of cortisol increased and were significantly associated with Dex IC50, which further suggest that cortisol-related metabolites are upregulated and associated strongly with Dex IC50 measure in AA women within the first trimester (See Supplementary Table S3). And finally, our study did not include an assessment of offspring health outcomes, which could further inform the consequences of early pregnancy GR, observed in AA women.

In conclusion, this study of AA pregnant women during their first trimester utilized HRM to identify GR-associated dysregulation of maternal metabolic pathways with the potential to influence maternal health and/or offspring development. These pathways are linked to increases in inflammatory metabolites, oxidative stress related metabolites, increased demand for functional amino acids to cope with growth and development, and disruption in energy related metabolism. Given the high prevalence of adverse pregnancy outcomes among AA women of all SES levels compared to white women, future studies are essential to provide an additional foundation for interventions or monitoring strategies related to stress and coping that will eliminate this persistent health disparity and improve the maternal and childhood health of all members of our population.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was funded by grants from the National Institutes of Health R01NR4800; R01NR4800; and P50ES026071.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cjence.2020.100001.

References

[1] R.S. Chirgure, L.L. Elias, I.M. da Silva Jr., J.G. Vieira, A.C. Moreira, M. de Castro, Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies, J. Clin. Endocrinol. Metab. 90 (11) (2005) 5978–5984.
[2] C. Leistner, A. Menke, How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders, Psychoneuroendocrinology 91 (2018) 255–260.
[3] T.W. Pace, F. Hu, A.H. Miller, Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression, Brain Behav. Immun. 21 (1) (2007) 9–19.
[4] A.J. Perrin, M.A. Horowitz, J. Roelofs, P.A. Sunszain, C.M. Pariante, Glucocorticoid resistance: is it a requisite for increased cytokine production in depression? A systematic review and meta-analysis, Front. Psychiatr. 10 (2019) 423.
[5] C. Delbende, C. Delarue, H. Lefebvre, D.T. Bunel, A. Szafarczyk, E. Mocaer, A. Kamoun, S. Jegou, H. Vaudry, Glucocorticoids, transmitters and stress, Br. J. Clin. Pharmacol. 62 (4) (2006) 287–298.
[6] J. Li, Y.P. Lu, C. Reichetzeder, P. Kalk, B. Kleuer, J. Adanski, B. Hocher, Maternal PxCasC8R6 is associated with preterm birth - a risk factor for early and late adverse outcome of the offspring, Kidney Blood Press. Res. 41 (3) (2016a) 250–257.
[7] M.M. Thomas, K. Sulek, E.J. McKenzie, B. Tan, H.L. Han, S.G. Villas-Boas, L.C. Kenny, L.M.E. McCowan, P.N. Baker, Metabolite profile of cervicovaginal fluids from early pregnancy is not predictive of spontaneous preterm birth, Int. J. Mol. Sci. 16 (11) (2015) 27741–27748.
[8] R.B. Behrmann, A.S. Butler, Preterm Birth: Causes, Consequences, and Prevention, National Academies Press, (US)Washington DC, 2007.
[9] E.J. Corwin, C.J. Hogan, B. Pears, E.J. Corwin, B. Spragg, T.D. Read, J. Mule, A.L. Dunlop, Protocol for the Emory University African American Vaginal, oral, and gut microbiome in pregnancy cohort study, BMC Pregnancy Childbirth 17 (1) (2017) 161.
[10] G.J. Miller, S. Cohen, A.K. Ritchey, Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model, Health Psychol. 21 (6) (2002) 531–541.
[11] M. Bekkhat, S.A. Rowson, G.N. Neigh, Checks and balances: the glucocorticoid receptor and NFkB in good times and bad, Front. Neuroendocrinol. 46 (2016) 15–31.
[12] B.D. Pearse, C.A. Biron, A.H. Miller, Neuroendocrine-immune interactions during viral infections, Adv. Virus Res. 56 (2001) 469–513.
[13] Y.M. Go, D.I. Walker, Y. Liang, K. Uppal, Q.A. Soltow, V. Tran, F. Strobel, A.A. Quyyumi, T.R. Ziegler, K.D. Pennell, G.W. Miller, D.P. Jones, Reference standardization for mass spectrometry and high-resolution metabolomics applications to exposure research, Toxicol. Sci. 148 (2) (2015) 531–543.
[14] J.M. Johnson, T. Yu, F.H. Strobel, D.P. Jones, A practical approach to detect unique metabolic patterns for personalized medicine, Analyst 135 (11) (2010) 2864–2870.
[15] T. Yu, Y. Park, S. Li, D.P. Jones, Hybrid feature detection and information accumulation using high resolution LC-MS metabolomics data, J. Proteome Res. 12 (3) (2013) 1419–1427.
[16] K. Uppal, Q.A. Soltow, F.H. Strobel, W.S. Pittard, K.M. Gernert, T. Yu, D.P. Jones, xMsAnalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data, BMC Bioinform. 14 (2013) 135.
[17] W.E. Johnson, C. Li, A. Rabinovich, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics (8) (2) (2007) 118–127.
[18] K. Uppal, D.I. Walker, D.P. Jones, xMsStamantor: an R package for network-based analysis of high-resolution metabolomics data, Anal. Chem. 89 (2) (2017) 1063–1067.
[19] E.L. Schymanski, J. Jeon, R. Gulde, K. Fenner, M. Ruff, H.P. Singer, J. Hollender, Identifying small molecules via high resolution mass spectrometry: communicating annotation of high-resolution metabolomics data, Anal. Chem. 89 (2017) 3051–3056.
[20] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, K. Morishima, KEGG: new features and developments, Nucleic Acids Res. 41 (2013) D801–D807.
[21] J.M. for “Precision, Pharmacometabolomics Task Group”-Metabolomics Society, I., K. Suhre, G. Kastenmüller, S.J. Sumner, I. Thiele, O. Fiehn, R. Kaddurah-Daouk, Metabolomics enables precision medicine: “A white paper, community perspective”, National Academies Press, (US)Washington DC, 2007.
[22] M. for “Precision, Pharmacometabolomics Task Group”-Metabolomics Society, I., K. Suhre, G. Kastenmüller, S.J. Sumner, I. Thiele, O. Fiehn, R. Kaddurah-Daouk, Metabolomics enables precision medicine: “A white paper, community perspective”, National Academies Press, (US)Washington DC, 2007.
[23] W.E. Johnson, C. Li, A. Rabinovich, Adjusting batch effects in microarray expression data using empirical Bayes methods, Biostatistics (8) (2) (2007) 118–127.
[24] K. Uppal, D.I. Walker, D.P. Jones, xMsStamantor: an R package for network-based analysis of high-resolution metabolomics data, Anal. Chem. 89 (2) (2017) 1063–1067.
[25] E.L. Schymanski, J. Jeon, R. Gulde, K. Fenner, M. Ruff, H.P. Singer, J. Hollender, Identifying small molecules via high resolution mass spectrometry: communicating confidence, Environ. Sci. Technol. 48 (4) (2014) 2097–2101.
[26] D.S. Wishart, T. Lewison, A.C. Guo, M. Wilson, C. Knox, Y. Liu, D. Yajm, R. Mandal, F. Aziz, E. Dong, S. Boustain, I. Selnickov, D. Arndt, J. Xia, P. Liu, F. Yalisu, T. Björndal, R. Perez-Fineiro, E. Reiser, F. Allen, V. Neuvz, R. Greiner, A. Schreiber, HMDB 3.0: the human metabolome database in 2013, Nucleic Acids Res. 41 (2013) D801–D807 (Database issue).
[27] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, K. Morishima, KEGG: new perspectives on genomes, pathways, diseases and drugs, Nucleic Acids Res. 45 (2017) D333–D351.
[28] C.A. Smith, G. O’Maille, E.J. Want, C. Qin, S.A. Trauger, T.R. Brandon, D.E. Custodio, R. Abagyan, G. Siuzdak, METLIN: a metabolite mass spectral database, Ther. Drug Monit. 27 (6) (2005) 747–751.
[29] S. Li, Y. Park, S. Durairasingham, F.H. Strobel, N. Kibbe, Q.A. Soltow, D.P. Jones, B. Pulendran, Predicting network activity from high throughput metabolomics, PLoS Comput. Biol. 9 (7) (2013b), e1003123.
[30] K. Uppal, D.I. Walker, K. Liu, S. Li, Y.M. Go, D.P. Jones, Computational metabolomics: a framework for the 21st metabolome, Chem. Res. Toxicol. 29 (12) (2016) 1956–1975.
[31] J. Xia, D.S. Wishart, Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis, Curr. Protoc. Bioinfor. 55 (2016) 14 10 –14 10 91.
N. Rahimi, F. Razi, E. Nasli-Esfahani, M. Qorbani, N. Shirzad, B. Larijani, Amino G. Wu, Functional amino acids in growth, reproduction, and health, Adv. Nutr. 1 (2010) 1669–1680.

D.P. Jones, H.D. True, J. Patel, Leukocyte trafficking in cardiovascular disease: insights from experimental models, Mediat. Inflamm. 2017 (2017) 9746169.

A. Lopez-Candales, P.M. Hernandez Burgos, D.P. Hernandez-Suarez, D. Harris, Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome, J. Nutr. Sci. 3 (2014) 7.

N.D. Steptoe, G. Wardle, Social disadvantage and cardiovascular disease, Clin. Sci. (Lond.) 131 (7) (2016) 739–750.

K.L. King, J.C. King, The role of maternal nutritional depletion and poor outcomes increases in early or closely spaced pregnancies, J. Nutr. 133 (Suppl 2) (2003) 1732S–1736S.

Y.M. Go, D.P. Jones, Redox theory of aging: implications for health and disease, Clin. Sci. (Lond.) 131 (14) (2016) 1669–1680.

D.P. Jones, H.D. True, J. Patel, Leukocyte trafficking in cardiovascular disease: insights from experimental models, Mediat. Inflamm. 2017 (2017) 9746169.

M.S. Schimmel, R. Bromiker, C. Hammerman, L. Chertman, A. Ioscovich, C. Eisen, Stress-activated signaling pathways in regulating gastrointestinal function, Dig. Dis. Sci. 54 (1) (2009) 14716.

P. Verheij, R. Rose, X.H. Lin, B. Yao, W.D. Jarvis, S. Grant, M.J. Birrer, E. Szabo, L.I. Zou, J.M. Kyriakis, A. Haimovitz-Friedman, Z. Paks, R.N. Kolesnick, Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis, Nature 380 (1996) 75–79.

T.W. Pace, K. Wingensfeld, I. Schmidt, G. Meilichschmidt, D.H. Hellhammer, C.M. Heim, Increased peripheral NF-kappaB pathway activity in women with childhood abuse-related posttraumatic stress disorder, Brain Behav. Immun. 26 (2012) 13–17.

M. Berger, Z. Sarnyai, ‘More than skin deep’: stress neurobiology and mental health consequences of racial discrimination, Stress 18 (1) (2015) 1–10.

J.H. Beard, C.N. Morrison, S.F. Jacoby, B.D. Dong, R. Smith, C.A. Sims, D.J. Wiebe, Quantifying disparities in urban firearm violence by race and place in Philadelphia, Pennsylvania: a cartographic study, Am. J. Publ. Health 107 (3) (2017) 371–373.

J. Galin, B. Abrams, S.A. Leonard, E.C. Matthey, D.E. Goin, J. Abem, Living in violent neighbourhoods is associated with gestational weight gain outside the recommended range, Paediatr. Perinat. Epidemiol. 31 (1) (2017) 37–46.

N.A. Mode, M.K. Evans, A.B. Zonderman, Race, neighborhood economic status, income inequality and mortality, PloS One 11 (5) (2016).

E.A. DeFranco, E.S. Hall, L.I. Mugla, Racial disparity in preivable birth, Am. J. Obstet. Gynecol. 214 (3) (2016) 394 e1–7.

J.A. Martin, B.E. Hamilton, M.J. Osterman, A.K. Driscoll, T.J. Matthews, Births: final data for 2015, Natl. Vital Stat. Rep. 66 (1) (2017) 1.

C.F. Rider, C. Carlsten, Air pollution and resistance to insulin glucocorticoid: evidence, mechanisms and gaps to fill, Pharmacol. Ther. 194 (2019) 1–21.

E.H. Bel, Smoking: a neglected cause of glucocorticoid resistance in asthma, Am. J. Respir. Crit. Care Med. 168 (11) (2003) 1265–1266.

Y. Zheng, D. Albert, R.J. McMahon, K. Dodge, D. Dick, G. Conduct Problems Prevention Research, Glucocorticoid receptor (NR3C1) gene polymorphism moderate intervention effects on the developmental trajectory of african-American adolescent alcohol abuse, Prev. Sci. 19 (1) (2018) 79–89.

A.L. Fowden, J. Li, A.J. Forhead, Glucocorticoids and the preparation for life after birth: are there long-term consequences of the life insurance? Proc. Nutr. Soc. 57 (1) (1998) 113–122.

G. Wu, Functional amino acids in growth, reproduction, and health, Adv. Nutr. 1 (2010) 31–37.

N. Rahimi, F. Razi, E. Natli-Esfahani, M. Qorbani, N. Shirzad, B. Larijani, Amino acid profiling in the gestational diabetes mellitus, J. Diabetes Metab. Disord. 16 (2017) 13.

H. Besedovsky, A. del Rey, E. Sorkin, C.A. Dinarello, Immuno-regulatory feedback between interleukin-1 and glucocorticoid hormones, Science 233 (4762) (1986) 652–654.

G.E. Miller, E. Chen, A.K. Fok, H. Walker, A. Lim, E.F. Nicholls, S. Cole, M.S. Kobor, Low birth weight: a complex disease myeloid cytokine and inflammatory network, J. Leukocyte Biol. 90 (4) (2011) 541–549.

A.S. Kaufman, K. Bokovska, E.F. Risman, Critical periods of susceptibility to short-term energy challenge during pregnancy: impact on fertility and offspring development, Physiol. Behav. 99 (1) (2010) 100–108.

V.K. Hogan, J.L. Richardson, C.D. Ferre, T. Durant, M. Boiseau, A public health framework for addressing black and white disparities in preterm delivery (1972), Am. J. Obstet. Gynecol. 193 (3 Pt 1) (2005) 626–635.

E. Corwin et al. Comprehensive Psychoneuroendocrinology 1-2 (2020) 100001